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Reprogramming somatic cells to induced pluripotent
stem cells (iPSCs) resets their identity back to an
embryonicageand, thus,presentsasignificanthurdle
for modeling late-onset disorders. In this study, we
describe a strategy for inducing aging-related fea-
tures in human iPSC-derived lineages and apply it
to the modeling of Parkinson’s disease (PD). Our
approach involvesexpressionofprogerin, a truncated
form of lamin A associated with premature aging. We
found that expression of progerin in iPSC-derived fi-
broblasts and neurons inducesmultiple aging-related
markers and characteristics, including dopamine-
specific phenotypes such as neuromelanin accumu-
lation. Induced aging in PD iPSC-derived dopamine
neurons revealed disease phenotypes that require
both aging and genetic susceptibility, such as pro-
nounced dendrite degeneration, progressive loss of
tyrosine hydroxylase (TH) expression, and enlarged
mitochondria or Lewy-body-precursor inclusions.
Thus, our study suggests that progerin-inducedaging
can be used to reveal late-onset age-related disease
features in hiPSC-based disease models.
INTRODUCTION
Late-onset neurodegenerative disorders such as Parkinson’s
disease (PD) are becoming a growing burden to society due to
the gradual increase in life expectancy. The incidence of PD
will likely continue to rise because it is estimated that by 2050,
21.8% of the projected world population (approximately twoCellbillion people) will be over 60 years of age (Lutz et al., 2008).
The use of induced pluripotent stem cell (iPSC) technology
where patient-derived skin cells can be reprogrammed back to
a pluripotent state and then further differentiated into disease-
relevant cell types presents new opportunities for modeling
and potentially treating currently intractable human disorders
(Bellin et al., 2012). However, there is a concern as to how well
iPSC-derived cells can model late-onset diseases where
patients do not develop symptoms until later in life, implicating
age as a necessary component to disease progression. Several
iPSC studies have demonstrated a loss of particular age-associ-
ated features during iPSC induction (reviewed in Freije and
Lo´pez-Otı´n, 2012; Mahmoudi and Brunet, 2012). For instance,
there is evidence for an increase in telomere length (Agarwal
et al., 2010; Marion et al., 2009) and mitochondrial fitness (Pri-
gione et al., 2010; Suhr et al., 2010) and loss of senescence
markers (Lapasset et al., 2011) in iPSCs derived from old donors,
suggesting that rejuvenation takes place during reprogramming.
In addition to the apparent loss of age-associated features in
iPSCs, the directed differentiation of human pluripotent stem
cells (hPSCs) is known to yield immature, embryonic-like cell
types that often require months of maturation to establish robust
functional properties (Liu et al., 2012a; Saha and Jaenisch,
2009). Protracted differentiation is thought to reflect the slow
timing of human development. For example, human midbrain
dopamine (mDA) neurons, a cell type affected in PD, require
months of differentiation to developmature physiological behav-
iors and to rescue dopamine deficits in animal models of PD
(Isacson and Deacon, 1997; Kriks et al., 2011). These in vitro
differentiation data argue for a species-specific, intrinsic
‘‘clock-like’’ mechanism that prevents the rapid generation of
mature, and aged, cells posing a challenge for human iPSC-
based modeling of late-onset disorders.
A key problem in addressing global aspects of aging and
rejuvenation during cell reprogramming is the identification ofStem Cell 13, 691–705, December 5, 2013 ª2013 Elsevier Inc. 691
Figure 1. Old Donor Fibroblasts Lose Age-Associated Markers following Reprogramming to the Pluripotent State
(A) Immunocytochemistry shows markers identifying the nuclear lamina (lamin A/C), a lamina-associated protein (LAP2a), and peripheral heterochromatin
(H3K9me3 and HP1g) in young fibroblasts (11-year-old donor) compared to old fibroblasts (82-year-old donor). Percentages indicate the proportion of cells with
folded and/or blebbed nuclear morphologies.
(legend continued on next page)
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cellular markers have been described in fibroblasts derived from
patients with Hutchinson-Gilford progeria syndrome (HGPS)
(Scaffidi and Misteli, 2005, 2006). HGPS is a rare genetic disor-
der characterized by premature aging of various tissues resulting
in early death (Hennekam, 2006). Mutations in LMNA, the gene
coding for the nuclear envelope protein lamin A, result in the
activation of a cryptic splice site that produces a shorter tran-
script known as progerin. Progerin protein aberrantly accumu-
lates in the nuclear membrane, preventing at least some of the
normal scaffolding functions of lamin A, which in turn interferes
with multiple processes in the nucleus, including chromatin
organization, heterochromatin formation, the DNA-damage
response, cell cycle, gene transcription, and telomere mainte-
nance (reviewed in Dechat et al., 2008). Interestingly, low levels
of progerin are expressed in healthy individuals, and a similar
age-associated profile has been observed in fibroblasts from
normally aged donors (Scaffidi and Misteli, 2006).
Here, we utilize a set of markers that correlates with fibroblast
donor age, includingmarkers of nuclear morphology and expres-
sion of nuclear organization proteins aswell asmarkers of hetero-
chromatin, DNA damage, and reactive oxygen species (ROS).
Such age-associated markers, present in old fibroblasts, were
lost during reprogramming and were not reacquired during the
subsequent differentiation, indicating that iPSC-derived cells do
not maintain a memory of their age. Importantly, we could induce
tissue-specific age-associated markers in both iPSC-derived
fibroblasts (iPSC-fibroblasts) and iPSC-derived mDA neurons
(iPSC-mDA neurons) following short-term progerin exposure.
The ability to rapidly induce features associated with cellular
agewascaptured to improvemodelingPD invitroandupon trans-
plantation of iPSC-mDA neurons in vivo. We observed several
age- and disease-related phenotypes not seen in previous iPSC
studies, including evidence of dendrite degeneration, the forma-
tion of age-associated neuromelanin, AKT deregulation, reduc-
tion in the number of TH+ neurons, and ultrastructural evidence
of mitochondrial swelling and inclusion bodies. Induced aging
presents a paradigm for iPSC studies that may be applicable to
other cell types and disease pathologies to address the contribu-
tionof geneticandage-associated factors in late-onsetdisorders.
RESULTS
Reprogramming Reverts Age-Associated Markers to a
‘‘Young’’ State
In order to validate a marker profile that could be followed during
reprogramming and redifferentiation, we compared 12 passage-(B) Quantification of themarkers depicted in (A) demonstrates the ability of the sele
the similarity of old donor fibroblasts to HGPS patient fibroblasts. The data are p
from single fibroblast lines that were passage matched. a.u., arbitrary units.
(C) Similar to HGPS patient fibroblasts, old donor fibroblasts have higher levels of
mtROS (measured by flow cytometry using the superoxide indicator MitoSOX) th
(D) Immunocytochemistry shows age-associated markers in passage 10 (P10) iP
(E) Quantification of staining in (D) indicates loss of age-associated markers durin
n = 300 cells each (100 cells from three independent iPSC clones).
(F) DNA damage and mtROS levels are reset upon reprogramming (n = 3 indepe
n.s., not significant. *p < 0.05, **p < 0.01, and ****p < 0.0001, according to Kolmogo
mean ± SEM. Scale bars, 50 mm (A) and 100 mm (D).
See also Figures S1 and S7, and Tables S1, S2, S4 and S5.
Cellmatched fibroblast populations from apparently healthy young
donors (age 11), middle-aged donors (ages 31–55), old donors
(ages 71–96), and prematurely aged patients with HGPS (ages
3–14) (Table S1 available online). We observed a significant
correlation of donor fibroblast age with age-associated markers
(Figures 1A–1C and S1A), including markers previously
described in HGPS fibroblasts (Scaffidi andMisteli, 2006). Fibro-
blasts from old donors resembled HGPS fibroblasts supporting
previous findings by Misteli and colleagues (Scaffidi and Misteli,
2005, 2006). More specifically, old donor fibroblasts showed
nuclear morphology abnormalities (i.e., folding and blebbing),
loss of the nuclear lamina-associated protein 2a (LAP2a), global
loss of the heterochromatin markers trimethylated H3K9
(H3K9me3) and heterochromatin protein 1 g (HP1g), as well as
an increase in DNA damage and mitochondrial reactive oxygen
species (mtROS) levels when compared to fibroblasts from
younger donors. Importantly, marker expression in old donor fi-
broblasts was comparable to HGPS fibroblasts despite express-
ing low levels of progerin, the mutant protein involved in HGPS
(Figure S1B; Table S2). These data suggest that age-associated
markers can faithfully stratify young versus old donor fibroblasts.
To address the effects of reprogramming on markers of
cellular age, we selected fibroblasts from young (age 11), old
(age 82), and HGPS (age 14) donors and transduced them with
Sendai vectors expressing Oct4, Sox2, Klf4, and c-Myc (Fusaki
et al., 2009) (Figure S1C). The use of the cytoplasmic RNA
viruses allowed for the derivation of integration-free iPSCs by
25–40 days posttransduction. All iPSC clones demonstrated
pluripotent properties and marker expression (Figures S1D–
S1F) and had a normal karyotype (data not shown), and iPSCs
derived from HGPS patient fibroblasts maintained the disease
mutation (Figure S1G). We next reassessed the age-associated
molecular markers shown above to distinguish between young
and old fibroblasts. iPSCs were not assessed prior to passage
10 to ensure loss of the exogenous Sendai virus (Figure S1D).
Following reprogramming, iPSCs that were derived from old
donor fibroblasts were indistinguishable from young donor-
derived iPSCs with respect to expression of lamin A, LAP2a,
H3K9me, and HP1g (Figures 1D and 1E). Furthermore, all iPSCs
displayed minimal levels of DNA damage or mtROS (Figure 1F),
suggesting a reset of phenotypic age. However, the age-associ-
ated signature could be dependent on progerin expression
(Scaffidi and Misteli, 2006), and the absence of an age-related
phenotype in iPSCs may simply reflect the fact that pluripotent
cells do not express A-type lamins including progerin (Constan-
tinescu et al., 2006). Immunocytochemical analysis for all A-type
lamin isoforms showed expression restricted to cells undergoingcted age-associatedmarkers to stratify young versus old donor fibroblasts and
lotted as frequency distributions of relative fluorescence intensity for 100 cells
DNA damage (measured by gH2AX immunocytochemistry) and higher levels of
an young donor fibroblasts (n = 3 independent experiments).
SCs derived from the young and old donor fibroblasts.
g reprogramming of old donor-derived iPSCs (similar to HGPS-derived iPSCs).
ndent clones).
rov-Smirnov tests (B and E) or Student’s t tests (C and F). Bar graphs represent
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Figure 2. iPSC-Fibroblasts from Old Donors Do Not Regain Age-
Associated Markers
(A) Immunocytochemistry for age-associated markers is presented. Percent-
ages indicate the proportion of cells with folded and/or blebbed nuclear
morphologies. Scale bar, 50 mm.
(B) Quantification of the markers shown in (A) indicates the high degree of
overlap between iPSC-fibroblasts from young and old donors compared to
HGPS iPSC-fibroblasts, which reestablish an age-like phenotype.
(C) Analysis of DNA damage (left) and mitochondrial superoxide (right) further
shows that iPSC-fibroblasts from old donors have been reset to a ‘‘young’’-like
state.
**p < 0.01 and ****p < 0.0001, according to Kolmogorov-Smirnov tests (B) or
Student’s t tests (C). n = 3 differentiations of independent iPSC clones
performed at different times. Bar graphs represent mean ± SEM.
See also Figures S2 and S7, and Tables S4 and S5.
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(Figure 1D, left column). HGPS iPSCs demonstrated a compara-
ble loss of age-associated markers at the pluripotent stage,
(Figures 1B, 1C, 1E, and 1F). However, despite the loss of age-
related markers, our data do not rule out the possibility that
reprogramming selects for cells with low levels of age-related
marker expression (a ‘‘young’’ cell) among the old donor fibro-
blasts rather than truly resetting age. Interestingly, clonal growth
of primary donor fibroblasts resulted in cultures that reestab-
lished a distribution of age-related markers comparable to the
original fibroblast population within 2 weeks (data not shown).
Therefore, it was not possible to obtain fibroblast populations
homogeneous in the expression of age-related markers. Never-
theless, regardless of the mechanism, our results demonstrate
that iPSCs, independent of donor age or HGPS status, lack
expression of age-associated markers.
Age Is Not Induced after Differentiating iPSCs Derived
from Old Donors
We next tested whether old donor-derived iPSCs may retain a
memory of their donor age that is transiently suppressed at the
pluripotent stage. We differentiated iPSCs back into fibroblast-
like cells using serum-containing medium (Figure S2A) for
30 days followed by fluorescence-activated cell sorting (FACS)
for CD13+/HLA-ABChi (Papapetrou et al., 2009; Verlinden et al.,
1981) (Figure S2B). The purified cells were expanded for an addi-
tional 30 days prior to characterization for the fibroblast marker
vimentin and absence of the neural precursor marker nestin (Fig-
ure S2C). iPSC-fibroblasts showed expression of lamin A and
progerin at levels similar to those observed in primary donor
fibroblasts (Figure S2D). However, differentiation did not rees-
tablish the age-associated marker profile in old donor iPSC-
fibroblasts (Figures 2A–2C) that closely matched the profile of
passage-matched young donor iPSC-fibroblasts. These data
demonstrate that age-associated markers in primary fibroblasts
from aged, apparently healthy donors are reset following reprog-
ramming and are not reestablished upon differentiation into
iPSC-fibroblasts. Thus, age is lost after reprogramming, giving
rise to phenotypically young iPSC-fibroblasts that may require
years of in vitro culture to reestablish their age. In contrast,
HGPS iPSC-fibroblasts did spontaneously reestablish expres-
sion of age-associated markers upon differentiation (Figures
2B and 2C) as reported in iPSC-based models of HGPS (Liu
et al., 2011; Zhang et al., 2011), suggesting that cues such asc.
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to an aged-like state.
Acute Progerin Overexpression Reestablishes Age-
Related Markers in iPSC-Fibroblasts
We next sought to determine whether progerin overexpression
is sufficient to induce age-associated markers in apparently
healthy young or old donor iPSC-fibroblasts. Synthetic mRNA
(termed modified-RNA) (Kariko´ et al., 2005; Warren et al., 2010)
was used to overexpress either GFP fused to progerin (GFP-
progerin) or a nuclear-localized GFP control (nuclear-GFP; Fig-
ure S2E; Table S2), allowing for easy manipulation of the amount
and duration of expression. Daily transfection of modified-RNA
for 3 days (Figure 3A) induced progerin expression to levels
similar or higher than those inHGPS iPSC-fibroblasts (FigureS2F,
arrows). Strikingly, overexpression of GFP-progerin but not
nuclear-GFP in young and old donor iPSC-fibroblasts induced
nuclear morphology abnormalities, loss of LAP2a expression,
formation of DNA double-strand breaks (gH2AX), loss of hetero-
chromatin markers (H3K9me3 and HP1g), and increasedmtROS
(Figures 3B–3D). These progerin-induced features were indistin-
guishable from those observed in primary fibroblasts from aged
donors (Figures 1A–1C andS1A). Aging inmitotic cells is typically
associated with the shortening of telomeres to a critical point
when the cell undergoes senescence, reaching Hayflick’s limit
(Hayflick, 1965). Therefore, we measured telomere lengths using
quantitative fluorescence in situ hybridization (Canela et al., 2007)
in transfected iPSC-fibroblasts to determine whether progerin
can induce telomere shortening. Following progerin overexp-
ression, iPSC-fibroblasts demonstrated a decrease in overall
length and an increase in the percentage of short telomeres
with progerin overexpression (FigureS2G). This resultwas further
corroborated by an increase in senescence-activated b-galacto-
sidase (SA-b-gal) staining (Figure S2H). All progerin-induced
changes in iPSC-fibroblasts were independent of donor age.
Our observations indicate that progerin overexpression is suffi-
cient to rapidly induce phenotypes in iPSC-fibroblasts that phe-
nocopy aspects of normal aging.
Progerin Induces Neuronal Aging Phenotypes in iPSC-
mDA Neurons
We next tested whether progerin overexpression also induces
age-like phenotypes in a postmitotic cell type. Therefore, we
differentiated young and old donor iPSCs into mDA neurons, a
cell type affected in PD, using our previously established proto-
col (Kriks et al., 2011) (Figure S3A). Within 13 days, differentiated
iPSCs had converted into LMX1A/FOXA2-positive midbrain floor
plate precursors, an early stage of mDA neuron development
(Figure S3B). Immature mDA neurons at day 32 of differentiation
were transiently treated with mitomycin C to eliminate remaining
proliferating progenitors (Figure S3C). iPSC-mDA neurons that
were matured for an additional 6 weeks (day 70) continued to
express mDA markers such as FOXA2 and tyrosine hydroxylase
(TH) in all iPSC clones independent of donor age (Figures S3D
and S3E). Interestingly, iPSC-mDA neurons spontaneously
showed evidence of low-level nuclear folding concomitant with
the onset of endogenous lamin A expression (Figure S3F).
To achieve similar expression levels of progerin in iPSC-mDA
neurons as in the iPSC-fibroblasts, we extended modified-RNACellexposure to 5 days (Figure 4A), which induced progerin
levels exceeding the levels of endogenous lamin A (Figure 4B,
arrows). Following progerin overexpression, GFP+ cells showed
evidence of enhanced nuclear folding and blebbing and accu-
mulation of DNA damage (Figure 4C) and mtROS (Figure 4D).
However, in contrast to iPSC-fibroblasts (Figure 3), we did not
observe significant changes in LAP2a, H3K9me3, or HP1g in
neurons (Figure 4E). Positive SA-b-gal staining, a marker of
senescence, was also not detected in iPSC-mDA neurons.
These data demonstrate both shared and cell-type-specific
responses of iPSC-fibroblasts and mDA neurons to our in vitro
aging paradigm.
To further examine cell-type-specific responses to progerin
exposure, we investigated parameters associated with neuronal
aging in vivo such as degenerative changes in dendrite branch-
ing (Hof and Morrison, 2004). Remarkably, 5 days of progerin
exposure in differentiated (day 65) mDA neurons was sufficient
to induce a degenerative phenotype resulting in the breakdown
of established neurites (Figure 5A). No degeneration was
observed in cells transfected with nuclear-GFP mRNA. We
next assessed expression of MAP2, which specifically labels
dendrites (Bernhardt, 1984). Quantitative analysis showed a
marked reduction in average dendrite length following progerin
exposure in mDA neurons from both young and old donor iPSCs
(Figure 5B). Importantly, the percentages of iPSC-mDA neurons
expressing the dopamine neuron markers NURR1 and TH
remained unchanged, suggesting that the addition of progerin
did not simply induce toxicity (Figures S4A and S4B), in contrast
to the treatment with mitochondrial toxins such as CCCP that
rapidly induced mDA neuron marker loss (data not shown).
To further characterize the age-like phenotype in iPSC-mDA
neurons following progerin overexpression, we performed
gene expression analysis by RNA-seq. Principle component
analysis confirmed a reset in gene expression following reprog-
ramming and illustrated the similarity between iPSC-mDA
neurons from donors of different ages (Figure 5C). Furthermore,
progerin overexpression induced highly similar (p < 2.93 3
10321) changes in young and old donor iPSC-mDA neurons
(Figures 5C and S4C). Many of the overlapping progerin-induced
expression changes (Figure S4C; Table S3) have been previously
associated with processes involved in neuronal aging, including
axon degeneration/regeneration (TMSB10, TMSB4X,CCDC126,
TSNAX, NOSTRIN, and LAMC3), protein misfolding and aggre-
gation (NEDD8, PSMB3, PPIB, and UBC), oxidative stress
(ENHO, NDUFB6, ATP5L, PRDX4, FTL, ATOX1, and TNIP3),
DNA damage (NOP10 and TCEAL7), cell-cycle induction
(PCNA and MIR663A), and chromatin modification (PRDM1)
(Figure 5D). Induction of transcripts associated with age-like
processes was confirmed by analysis of gene ontology (Fig-
ure S4D). Among the differentially expressed transcripts, we
also found several uncharacterized genes and noncoding
RNAs (Figure 5E) reminiscent of recent observations in the aging
rat brain (Wood et al., 2013).
Progerin-Induced Aging Enables Modeling of Late-
Onset PD Features In Vitro and In Vivo
A key motivation for manipulating age in iPSC-neurons is the
need for developing faithful models of late-onset neurodegener-
ative disorders such as PD. Several groups have establishedStem Cell 13, 691–705, December 5, 2013 ª2013 Elsevier Inc. 695
Figure 3. Progerin Overexpression Induces Age-Associated Changes in iPSC-Fibroblasts Regardless of Donor Age
(A) Modified-RNA was transfected into iPSC-fibroblasts on 3 consecutive days prior to analysis on day 4.
(B) Overexpression of progerin (GFP-progerin) in iPSC-fibroblasts causes changes in nuclear morphology (as seen by GFP), expression of the LAP (LAP2a), levels
of DNA damage (gH2AX), and chromatin organization (H3K9me3; HP1g), which were not observed with overexpression of a nuclear-GFP. Percentages indicate
the proportion of cells with folded and/or blebbed nuclear morphologies. Scale bar, 25 mm.
(legend continued on next page)
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reported phenotypes in cell types of uncertain relevance for PD
such as neural stem cells (Liu et al., 2012b) or early biochemical
phenotypes in mDA neurons without modeling the severe neuro-
degenerative features of the disease (Cooper et al., 2012;
Nguyen et al., 2011; Seibler et al., 2011). We hypothesized that
the lack of a neurodegenerative phenotype in those studies
may be a result of the age reset during reprogramming. Similar
to patients with PD who do not exhibit disease symptoms until
later in life, PD iPSC-mDA neurons may be too ‘‘young’’ to mimic
the degenerative phase of the disease. Therefore, we tested
whether progerin overexpression may reveal disease-associ-
ated phenotypes that cannot be currently modeled in PD iPSC
studies. We derived mDA neurons from PD iPSCs with homozy-
gous mutations (Figure S5A; Table S2) in PINK1 (Q456X) or
Parkin (V324A). PINK1 and Parkin are thought to act in a
common pathway to promote the autophagic degradation of
damaged mitochondria (Dodson and Guo, 2007), in addition to
the unique functions of Parkin in the ubiquitin-proteasome
pathway (Shimura et al., 2000).
PD iPSCs differentiated into mDA neurons with similar effi-
ciencies than iPSCs from apparently healthy donors (C1 and
C2; Figures S5B and S5C). Furthermore, PD and control iPSC-
mDA neurons (day 65), transfected with GFP-progerin or nu-
clear-GFP for 5 days, did not showchanges inNURR1 (Figure 6A)
or TH (Figure 6B) expression. We were particularly interested in
defining PD-related phenotypes that depend on induced
in vitro aging and thereby mimic the late-onset nature of the
disease. For instance, we observed a significant increase in
condensed nuclei that expressed cleaved caspase-3 in PD
versus control iPSC-mDA neurons (Figure 6C), indicating that
PD mutant mDA neurons are more prone to activating a cell
death program upon induced aging. GFP-progerin-positive
condensed nuclei were not detected until day 4 or day 5 of pro-
gerin transfection, suggesting a progressive decline rather than
an acute toxicity. Dendrite length in mDA neurons was not signif-
icantly affected in PD versus control iPSC-mDA neurons under
control conditions. However, following progerin overexpression,
loss of dendrite length was significantly enhanced in mDA
neurons derived from PINK1-Q456X and Parkin-V324A iPSCs
versus control iPSC-mDA neurons (Figures 6D and 6E).
It has been suggested that decreased neuronal survival in PD
is in part caused by diminished levels of phosphorylated S473
AKT (p-AKT), based on studies in PD models (Malagelada
et al., 2008; Tain et al., 2009) and in brain tissues from patients
with sporadic PD (Timmons et al., 2009). Interestingly, PINK1-
Q456X and Parkin-V324A mutant iPSC-mDA neurons showed
a significant reduction in p-AKT in response to progerin, whereas
C1 and C2 iPSC-mDA neurons showed a slight increase in
p-AKT (Figures 6F and 6G). The deregulation of AKT signaling
also resulted in the corresponding changes in the phosphoryla-(C) Quantification of data shown in (B) is presented. Frequency distribution plots
transfections of iPSC-fibroblasts derived from independent iPSC clones.
(D) Flow cytometry analysis of the mitochondrial superoxide indicator MitoSOX s
expression (n = 3 independent RNA transfections of iPSC-fibroblasts derived fro
*p < 0.05, **p < 0.01, and ****p < 0.0001, according to Kolmogorov-Smirnov tests
graphs represent mean ± SEM.
See also Figures S2 and S7, and Tables S2, S4, and S5.
Celltion of the downstream signaling targets ULK1 and 4EBP1 (Fig-
ures 6F and 6G). There was considerable variability in the basal
levels of AKT, ULK1, and 4EBP1 across replicate differentiations
independent of genotype and treatment (Figures 6F and S5D).
However, the progerin-induced reduction in the activation status
of AKT signaling components was consistent (independent of
basal levels) andmimicked the reported signaling changes in PD.
To further confirm the progerin-induced differences between
PD and control iPSC-mDA neurons, we reprogrammed addi-
tional fibroblasts from a patient with PD with a heterozygous
R275W Parkin mutation using Sendai virus-based reprogram-
ming. Similar to the progerin-induced phenotype in PINK1-
Q456X and Parkin-V324A, progerin overexpression drove
increased apoptosis (Figure 6C), enhanced dendrite shortening
(Figure 6E), and reduced AKT activation (Figure S5E) in Parkin-
R275W iPSC-mDA neurons compared to control iPSC-mDA
neurons (C3 and C4).
In order to assess the long-term effects of progerin exposure,
mDA neurons derived from PD and control iPSCs were trans-
duced with lentiviral vectors expressing GFP-progerin or
nuclear-GFP under the control of the neuron-specific human
synapsin (hSyn) promoter and grafted into the striatum of 6-
hydroxydopamine lesioned NOD-SCID IL2Rgc-null mice (Fig-
ure 7A). In vitro analysis of matched aliquots of cells 24 hr after
transplantation confirmed expression of NURR1 and TH in
GFP+ cells (Figure S6A). Onset of hSyn-driven transgene
expression in vitro was detectable 1 day prior to grafting, and
expression was maintained in cultured cells for at least
90 days (latest time point tested). In vivo analysis 3 months after
grafting resulted in a reduction of amphetamine-induced rotation
scores in most animals (Figure 7B), indicating mDA neuron sur-
vival above the threshold required for behavioral improvement.
Interestingly, the subset of animals that did not recover (Fig-
ure 7B, pink symbols) had received either PINK1- or Parkin-
derived neurons expressing progerin. Lack of recovery was
surprising considering that survival of only few mDA neurons is
required to rescue behavior. To address whether incomplete
behavioral recovery in the animals was due to a smaller number
of surviving mDA neurons, we performed stereological quantifi-
cation of the grafts. Although graft volume was not significantly
affected in progerin-treated versus control groups (data not
shown), progerin-expressing mDA neuron grafts showed a dra-
matic reduction in TH+ cell numbers (Figures 7C and 7D). Strik-
ingly, the reduction in TH+ cells was particularly pronounced in
progerin-expressing mDA neuron grafts from PINK1-Q456X
and Parkin-V324A iPSCs and minimal in control iPSC-mDA
neuron grafts. Those results mimic the accelerated loss of TH
observed in patients with PD, though the mechanism of TH+
cell loss in the current study remains to be determined.
To further assess biomarkers of age and disease status of the
iPSC-mDA neurons, we performed ultrastructural analysis of therepresent the fluorescence intensity of 100 cells from three independent RNA
uggests a dramatic increase in mitochondrial dysfunction with progerin over-
m independent iPSC clones).
(LAP2a, H3K9me3, and HP1g) or Student’s t tests (gH2AX and MitoSOX). Bar
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Figure 4. Progerin Overexpression Induces a Subset of the Fibroblast Age-Associated Signature in iPSC-mDA Neurons Derived from Both
Young and Old Donors
(A) Modified-RNA was transfected into iPSC-mDA neurons on 5 consecutive days prior to analysis on day 6.
(B) Western blot analysis of transgene expression is shown. A GFP band at 100 kDa denotes the GFP-progerin (+p) fusion protein, whereas a GFP band at 27 kDa
represents the nuclear-GFP (+n) transgene. All lamin A isoforms including the transgene were recognized by a single antibody. Note that progerin overexpression
levels exceed endogenous lamin A levels (arrows). iPSC-mDA neurons do not appear to express detectable levels of progerin protein endogenously.
(C) Progerin overexpression enhances nuclear folding and blebbing (as seen by lamin B2, pink) and increases DNA-damage accumulation (gH2AX) in both young
and old donor-derived iPSC-mDA neurons. Percentages indicate the proportion of cells with enhanced nuclear folding and/or blebbing or the proportion of cells
with greater than three enlarged gH2AX foci. Scale bars, 10 mm (bottom) and 25 mm (top).
(D) Flow cytometry analysis of mitochondrial superoxide levels (MitoSOX) demonstrates increasedmitochondrial dysfunction with progerin overexpression (n = 3
independent RNA transfections of iPSC-mDA neurons derived from independent iPSC clones). *p < 0.05, according to Student’s t tests.
(E) Quantification of immunocytochemistry for LAP2a, H3K9me3, and HP1g shows no difference between iPSC-mDA neurons transfected with GFP-progerin or
nuclear-GFP, unlike the phenotype observed in iPSC-fibroblasts (see Figure 3). Fluorescence intensities were normalized to the intensities observed in nuclear-
GFP-treated cells.
Bar graphs represent mean ± SEM.
See also Figures S3 and S7, and Tables S2, S4, and S5.
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Induced Aging for Modeling Late-Onset Diseasegrafts 6 months after transplantation by transmission electron
microscopy (TEM). Initial observations by light microscopy
demonstrated a continued, progressive loss of TH immuno-698 Cell Stem Cell 13, 691–705, December 5, 2013 ª2013 Elsevier Inreactivity in grafts overexpressing progerin (Figure S6B). Anal-
ysis by TEM confirmed the progerin-induced reduction of TH
expression in iPSC-mDA neuron dendrites and folded nuclearc.
Figure 5. Progerin Overexpression Elicits
Features Consistent with Neuronal Aging
in iPSC-mDA Neurons
(A) Immunocytochemistry for the pan-neuronal
marker TUJ1 shows a loss of the established
neuronal network in day-70 iPSC-mDA neurons
overexpressing progerin, but not iPSC-mDA
neurons overexpressing nuclear-GFP. Scale bar,
200 mm.
(B) MAP2 immunocytochemistry reveals reduced
intact dendrite lengths following overexpression of
progerin in most but not all (insets) iPSC-mDA
neurons derived from both young and old donors.
Frequency distributions display total dendrite
length measurements from three independent
RNA transfections (50 cells each, nonapoptotic
nuclei only). Scale bar, 50 mm. ****p < 0.0001,
according to Kolmogorov-Smirnov tests.
(C) Principal component analysis of RNA-seq gene
expression data further corroborates the re-
programming-induced reset of age that results in
the high similarity of iPSC-mDA neurons from both
young and old donors. Progerin overexpression
induces similar changes in mDA neurons inde-
pendent of donor age.
(D) The top 20 upregulated (left) and down-
regulated (right) genes in progerin-treated
compared to control nuclear-GFP-treated young
donor (green) and old donor (blue) iPSC-mDA
neurons are shown. Genes are ranked according
to iPSC-mDA neurons derived from the old donor.
Red denotes uncharacterized genes, and orange
denotes noncoding RNAs. Dotted line indicates
the threshold for significance.
(E) Pie charts represent the proportion of the
significantly differentially expressed transcripts
that are coding, noncoding, or uncharacterized.
See also Figures S4 and S7, and Tables S2, S3,
S4, and S5.
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Induced Aging for Modeling Late-Onset Diseasemorphologies (Figures S6C and S6D). To determine the age sta-
tus of the grafted neurons, we focused on the intracellular accu-
mulation of neuromelanin. Neuromelanin is a dark-colored
pigment present in adult mDA neurons but absent in fetal or
neonatal stages including iPSC-mDA neurons (Mann and Yates,
1974; Sulzer et al., 2008). In human fetal tissue transplantation
studies, neuromelanin was detected in grafts 4–14 years after in-
trastriatal injection, a time course similar to normal development
(Loh et al., 2010). In just 6 months, we observed robust accumu-
lation of neuromelanin with lipofuscin deposits selectively in
grafts overexpressing progerin (an average of eight depositsCell Stem Cell 13, 691–705,per 55 mm2 versus 0.5 in control nu-
clear-GFP-expressing grafts, Figure 7E)
and regardless of genetic background.
In addition, progerin overexpression
revealed genotype-specific effects in PD
iPSC-derived grafts, phenotypes not
observed in PD grafts overexpressing
nuclear-GFP, or in any non-PD control
grafts. For instance, signs of neurite
degeneration such as the appearance of
fibrillar bodies were prominent in PD-derived grafts overexpressing progerin (asterisks in Figures 7E,
7G, and S6C), indicating a breakdown of microtubules (Jaworski
et al., 2011). Furthermore, PINK1-Q456X grafts contained cells
with enlarged mitochondria, a phenotype much more pro-
nounced in progerin-overexpressing cells (area of 0.167 mm2
compared to 0.0387 mm2 for PINK1 plus nuclear-GFP; p =
0.0005; Figures 7F and S6F). In contrast, Parkin mutant grafts
showed less-dramatic mitochondrial defects (such as abnormal
mitochondrial fusion; data not shown) but, strikingly, exhibited
large multilamellar inclusions (Figure 7G). Multilamellar inclu-
sions have been observed in various neurodegenerative modelsDecember 5, 2013 ª2013 Elsevier Inc. 699
Figure 6. Progerin Overexpression Reveals Disease-Specific Phenotypes In Vitro in iPSC-Based Models of Genetic PD
(A and B) Quantification of NURR1+ cells (A) and western blot analysis of TH protein levels (B) do not reveal significant differences with transfection of GFP-
progerin (+p) modified-RNA. +n, nuclear-GFP. Numbers below the western blot indicate the ratio of GFP-progerin:nuclear-GFP expression of TH normalized to
GAPDH.
(C) Analysis of GFP+ cells undergoing cell death following RNA transfection as identified by condensed nuclear morphologies is shown. Images display a
representative example of cleaved caspase-3 immunocytochemistry in cells treated with progerin.
(D) Immunocytochemistry for the dendrite marker MAP2 is shown.
(E) Quantification of total dendrite lengths per GFP+ neuron shows accelerated dendrite shortening in PD mutant iPSC-mDA neurons compared to apparently
healthy controls (C1–C4) in response to progerin overexpression.
(F and G) Western blot analysis of AKT pathway signaling (F) demonstrates genotype-specific responses to progerin overexpression. For quantification,
phospho-specific bands (G) were normalized to total protein before calculating the ratio of the levels expressed following progerin versus nuclear-GFP treatment.
(legend continued on next page)
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a precursor to the characteristic Lewy bodies found in surviving
mDA neurons in brains from patients with PD (Fornai et al., 2004).
The presence of these neuronal inclusions suggests decreased
function of the ubiquitin-proteasome pathway due to the loss
of normal Parkin function. However, the dependence of the
phenotype on progerin expression suggests that age-related
factors contribute to this dysfunction.
Our in vivo results corroborate the in vitro data that the age of
iPSC-mDA neurons is reset to a ‘‘young’’ state not conducive
to modeling late-onset features of PD. In contrast, progerin-
induced neuronal aging reveals phenotypes consistent with
normal aging as well as disease-associated phenotypes that
reflect the synergistic interaction of genotype and age in
modeling late-onset degenerative aspects of PD.
DISCUSSION
The ability to measure and manipulate age in cells differentiated
from iPSCs represents a fundamental challenge in pluripotent
stem cell research that remains unresolved to date. There has
been considerable progress in directing cell fate into the various
derivatives of all three germ layers; however, there has been no
technology to switch the age of a given cell type on demand from
embryonic to neonatal, adult, or aged status. This remains a
major impediment in the field as illustrated by the persistent
failure to generate hiPSC-derived adult-like hematopoietic
stem cells, fully functional cardiomyocytes, or mature pancreatic
islets, and the general inability to derive aged cell types stage
appropriate for modeling late-onset diseases.
The current study represents an attempt at addressing these
challenges. We define a set of cellular markers that correlates
with the chronological age of donor fibroblasts, including
markers of nuclear organization, heterochromatin, DNAdamage,
and mitochondrial stress. We demonstrate a loss of these age-
associated markers upon reprogramming and report that
iPSC-derived lineages do not reacquire aging features upon
differentiation. We further show that in apparently healthy, non-
HGPS cells, progerin exposure is sufficient to induce the same
set of age-associated markers that defines the original old donor
fibroblast population prior to iPSC induction. Importantly, we
present an induced aging strategy that mimics several aspects
of normal aging in iPSC-derived lineages beyond fibroblasts
and demonstrate the utility of our approach for modeling late-
onset disorders such as PD (Figure S7; Table S4).
A critical requirement for our study was the identification of
markers that predict fibroblast donor age and that can be used
to monitor cellular age during reprogramming, differentiation,
and induced aging. In contrast to previous studies by Agarwal
et al. (2010), Marion et al. (2009), Prigione et al. (2010), and
Suhr et al. (2010), it was important to look at a broad set of
age-related markers and to compare cellular age in matchedDotted line indicates an equal amount of phospho protein in both treatment c
genotype.
*p < 0.05, **p < 0.01, and ***p < 0.001, according to one-way ANOVAwith Dunnett’
cases). Bar graphs represent mean ± SEM. +n, nuclear-GFP; +p, GFP-progerin;
retroviral factors; (S), iPSC derived using Sendai viral factors. Scale bars, 25 mm
See also Figures S5 and S7, and Tables S2 and S5.
Cellcell fates (donor fibroblast versus iPSC-fibroblast). Future
studies may include additional candidate markers such as
methylation levels at particular CpG sites that have been re-
ported to predict donor age across multiple tissues (Hannum
et al., 2013; Koch and Wagner, 2011) or methylation patterns
reported to reflect epigenetic memory in iPSCs of donor cell
fate (Kim et al., 2010; Polo et al., 2010). It will also be interesting
to include additional fibroblast lines covering the age spectrum
at even higher resolution and to define whether age-related
marker expression increases gradually or occurs as a binary
‘‘off/on’’ switch between young and old age.
One interesting aspect of our approach is the ability to induce
cell-type-specific responses (Table S4). Progerin exposure can
not only reestablish age in fibroblasts but also phenocopies
aspects of normal neuronal aging, including the presence of
neuromelanin in grafted mDA neurons, global transcriptional
changes in mDA neurons after progerin exposure, and pro-
gerin-induced in vitro dendrite degeneration phenotypes.
Furthermore, our results indicate that progerin levels may affect
the timing by which age-related phenotypes appear. The use of
modified-RNAs rapidly induced very high levels of expression
and triggered age-related marker expression within just 3 days
in fibroblasts and 5 days in neurons. In contrast, lentiviral expres-
sion under control of a neuronal-specific promoter led to much
lower levels of expression that did not trigger an obvious pheno-
type at 1 month after transplantation (data not shown) but
induced robust and progressive phenotypes at 3 and 6 months
postgrafting. Progerin-induced age-related phenotypes occur
much more rapidly than during normal aging, making induced
aging an attractive yet artificial strategy for modeling late-onset
pathology.
It is worth noting that progerin expression using modified-
RNAs or expression under a neuron-specific promoter bypasses
the differential progerin levels found across various tissues in
patients with HGPS. Tissue-specific expression of A-type lamins
is likely the reason why the disease does not affect all organ
systems equally (Ro¨ber et al., 1989). In particular, the CNS is
thought to be relatively protected due to the expression of
miR-9, which targets lamin A and progerin, but not lamin C
(Nissan et al., 2012). Therefore, HGPS iPSC-derived neurons
are likely not a suitable alternative to the use of progerin modi-
fied-RNA to trigger in vitro neuronal aging.
Although progerin exposure may not capture all aspects of
normal aging, our study demonstrates that the induced aging
strategy triggers an aged-like state suitable for modeling late-
onset diseases such as PD in a manner we have not known to
be previously possible in the iPSC field. We observed a robust
degenerative phenotype in two genetic PD iPSC models. In
future studies, it will be interesting to mechanistically dissect
the separate contribution of genetic and age-related disease
susceptibilities such as the differences observed in grafted
PINK1 versus Parkin mutant iPSC-mDA neurons using isogenic,onditions. Quantification represents three independent cell isolates for each
s tests (n = 3 independent differentiations andmodified-RNA transfections in all
C1–C4, lines derived from apparently healthy donors; (R), iPSC derived using
.
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Figure 7. Long-Term Progerin Overexpression In Vivo Reveals a Severe Degenerative Phenotype in PD Mutant Cells
(A) Schematic illustration represents the transplantation studies into 6-OHDA-lesioned Parkinsonian mice.
(B) Rotational behavior analysis of lesioned mice transplanted with control or PD mutant iPSC-mDA neurons expressing hSyn::nuclear-GFP or hSyn::GFP-
progerin is shown. Mice were lesioned and tested for amphetamine-induced rotation behavior twice prior to grafting. Dotted line indicates threshold for
successful lesioning. Pink symbols identify successfully lesioned animals that did not show recovery (n = 3–5 animals per treatment group).
(legend continued on next page)
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time course studies to further examine the progressive reduction
in TH+ neurons upon long-term exposure in vivo despite our
preliminary observations that there are comparable TH+ neuron
numbers at early time points after grafting. The ultrastructural
inclusions observed in Parkin-derived mDA neurons in vivo are
compatible with precursor lesions to Lewy body formation.
Because Lewy bodies are less frequently observed in patients
with PD with Parkin or PINK1 mutations (Nuytemans et al.,
2010), it will be intriguing to test our strategy in additional PD
subpopulations such as patients with mutations in a-synuclein
or LRRK2 or in sporadic PD. Finally, our technology could be
integrated into a drug discovery pipeline aimed at counteracting
the increased disease susceptibility of aged cells, a target that
cannot be pursued using current PD iPSC models where the
symptom-relevant cells appear ‘‘young’’ and resistant to the
degenerative aspect of the disease.
Our work will likely stimulate studies aimed at testing alter-
native and complementary ‘‘induced aging’’ strategies for
modeling late-onset disease. It will also be important to better
address the timeline and reversibility of induced aging in iPSC-
derived lineages. Furthermore, it will be interesting to test
whether expression of progerin at lower levels could facilitate
maturation of differentiated iPSC lineages, another key bottle-
neck in the field. We propose induced aging as a strategy com-
plementary to iPSC technology that may ultimately enable the
precise programming of both cell fate and age on demand.
EXPERIMENTAL PROCEDURES
iPSC Derivation and Differentiation
Apparently healthy young donor, old donor, and HGPS patient and Parkin-
son’s patient fibroblasts purchased from Coriell were reprogrammed as
described (Fusaki et al., 2009) using CytoTune Sendai viruses (Life Technolo-
gies) at an MOI of ten. iPSC clones were isolated approximately 4 weeks after
transduction and maintained on MEFs with weekly passaging using Dispase
(STEMCELL Technologies). For differentiation, iPSCs were harvested using
Accutase (Innovative Cell Technology). Fibroblast (Park et al., 2008) and
mDA neuron differentiations (Kriks et al., 2011) were performed as previously
described.
Modified-RNA Synthesis
Modified-RNA was generated using an in vitro transcription (IVT) protocol
described previously (Mandal and Rossi, 2013; Warren et al., 2010). Transfec-
tions were performed using Lipofectamine RNAiMAX (Life Technologies) in
cell-type-specific medium following treatment with an interferon inhibitor
(B18R; eBioscience).
Immunocytochemical Analyses
Cell cultures were fixed in 4% paraformaldehyde. A list of antibodies and
concentrations is provided in Table S5. Secondary antibodies were species-
specific Alexa dye conjugates (Molecular Probes). Additional details for mouse
tissue and quantification methods are described in the Supplemental(C) Assessment at 3 months posttransplant revealed a dramatic loss of TH+ mDA
(D) Quantification of the percentage of GFP+ cells that are TH+ is shown. Data are
according to Student’s t tests.
(E–G) Ultrastructural analysis 6 months after transplantation revealed accumulatio
progerin overexpression. Strikingly, the PINK1mutant graft with progerin displaye
orange arrows in +nuclear-GFP and +GFP-progerin groups), whereas the Parkin m
phenotypes were not observed in any other treatment groups. Asterisks in (E) and
Bar graph represents mean ± SEM.
See also Figures S6 and S7, and Tables S2, S4, and S5.
CellExperimental Procedures. Animal procedures were performed following NIH
guidelines and were approved by the local Institutional Animal Care and Use
Committee (IACUC).
Flow Cytometry and mtROS Analyses
Cells were dissociated with Accutase and stained with directly conjugated
antibodies (BD Biosciences). For mtROS assessment, cells were stained
with MitoSOX Red (Life Technologies) at a final concentration of 20 mM in
cell culture medium. Cell sorting was performed on a FACSAria (BD
Biosciences).
Gene Expression Analysis
Cells were lysed with TRIzol (Life Technologies). RNA was extracted using the
RNeasy kit (QIAGEN) and reverse transcribed using the SuperScript kit (Life
Technologies) according to the manufacturer’s instructions. Quantitative
RT-PCR was performed using the Mastercycler RealPlex2 (Eppendorf) plat-
form. For RNA-seq, total RNAwas isolated from two independent experiments
and processed by the MSKCC genomics core laboratory.
Protein Analysis
Cell pellets were lysed with RIPA buffer with 1% SDS. A total of 20–40 mg
samples were further diluted with 43 Laemmli sample buffer, boiled for
5 min at 95C, and loaded onto a NuPAGE 4%–12% Bis-Tris precast gel
(Life Technologies). PVDF membranes were incubated in primary antibodies
overnight (see Table S5 for a list of antibodies used) followed by appropriate
HRP-labeled secondary antibodies (Jackson ImmunoResearch).
Xenografts
iPSC-mDA neurons were transplanted into the striatum of lesionedNOD-SCID
IL2Rgc null mice (Jackson Laboratory) following in vitro transduction with
either hSyn::GFP-progerin or hSyn::nuclear-GFP lentivirus. Immunohisto-
chemistry of the grafts was quantified by stereological analyses. Electron
microscopy was performed 6 months following transplantation as described
(Milner et al., 2011).
Statistical Analyses
Distributions were compared by statistical analysis of corresponding cumula-
tive distributions using Kolmogorov-Smirnov tests to analyze the difference
between different ages or treatments. Bar graphs are plotted as mean ±
SEM and represent three independent biological replicates except where
noted. Two-group comparisons were analyzed using Student’s t tests. Multi-
ple-group comparisons against a control were analyzed using an ANOVA
with Dunnett’s test. Prism (version 6.0a; GraphPad) was used for data presen-
tation and analysis.
ACCESSION NUMBERS
The RNA-seq data are available at Gene Expression Omnibus (http://www.
ncbi.nlm.nih.gov/geo) under the accession number GSE52431.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and five tables and can be found with this article online at
http://dx.doi.org/10.1016/j.stem.2013.11.006.neurons in PD mutants overexpressing progerin. Scale bar, 200 mm.
presented as mean ± SEM (n = 3 mice per condition). *p < 0.05 and **p < 0.01,
n of neuromelanin with lipofuscin deposits (E, yellow arrowheads) in grafts with
d enlargedmitochondria (F, compare representative mitochondria indicated by
utant graft with progerin had large multilamellar bodies (G, pink arrows). These
(G) indicate a fibrillar body of degenerating microtubules. Scale bars, 500 nm.
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